{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:40:32Z","timestamp":1756464032089,"version":"3.44.0"},"reference-count":36,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:p>The prevalence of type 2 diabetes is rising, and in 2015 more than 5% of adults in the UK were affected by this condition.<jats:sup>1,2<\/jats:sup> Management of type 2 diabetes includes encouraging lifestyle changes (increased exercise, modification of diet and smoking cessation) alongside the provision of medication to minimise long-term complications and manage blood sugar control while avoiding unwanted effects of drug treatment.<jats:sup>3<\/jats:sup> Of particular importance, people with type 2 diabetes are at increased risk of cardiovascular disease, and therefore the aims of treatment also include modification of associated risk factors.<jats:sup>2-5<\/jats:sup>\n               <\/jats:p>\n               <jats:p>\u25bc Empagliflozin (Jardiance-Boehringer Ingelheim) is the third sodium-glucose co-transporter-2 (SGLT2) inhibitor licensed for use in the UK. It was launched in August 2014, and acts in a similar way to the other SGLT2 inhibitors, \u25bc dapagliflozin and \u25bc canagliflozin, by inhibiting renal glucose resorption and promoting glycosuria.<jats:sup>6<\/jats:sup> It is indicated for the treatment of type 2 diabetes in adults to improve glycaemic control, as monotherapy when metformin cannot be used, and in combination with other glucose-lowering drugs including insulin. Here we review the evidence for empagliflozin and discuss the results of a recent study that assessed cardiovascular outcomes.<\/jats:p>","DOI":"10.1136\/dtb.2016.6.0411","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T07:01:48Z","timestamp":1468479708000},"page":"78-81","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["\u25bc Empagliflozin, diabetes and outcomes"],"prefix":"10.1136","volume":"54","member":"239","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"key":"2025082700590595000_54.7.78.1","unstructured":"Diabetes UK, 2015. Key facts and stats [online]. Available: https:\/\/www.diabetes.org.uk\/About_us\/What-we-say\/Statistics\/ [Accessed 22 June 2016]."},{"key":"2025082700590595000_54.7.78.2","unstructured":"National Institute for Health and Care Excellence, 2015. Type 2 diabetes in adults: management (NG28) [online]. Available: https:\/\/www.nice.org.uk\/guidance\/ng28 [Accessed 22 June 2016]."},{"key":"2025082700590595000_54.7.78.3","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2013.4.0172"},{"key":"2025082700590595000_54.7.78.4","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0025"},{"key":"2025082700590595000_54.7.78.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-s011"},{"key":"2025082700590595000_54.7.78.6","unstructured":"Jardiance 10\u2005mg and 25\u2005mg film-coated tablets. Summary of product characteristics, EU. Boehringer Ingelheim International GmbH, April 2016."},{"key":"2025082700590595000_54.7.78.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60794-7"},{"key":"2025082700590595000_54.7.78.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"2025082700590595000_54.7.78.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2025082700590595000_54.7.78.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"2025082700590595000_54.7.78.11","unstructured":"European Medicines Agency, 2012. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129256.pdf [Accessed 22 June 2016]."},{"key":"2025082700590595000_54.7.78.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"},{"key":"2025082700590595000_54.7.78.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"2025082700590595000_54.7.78.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225"},{"key":"2025082700590595000_54.7.78.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02894.x"},{"key":"2025082700590595000_54.7.78.16","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.2147\/DDDT.S69926","article-title":"Empagliflozin in the treatment of type 2 diabetes: evidence to date","volume":"9","author":"Shubrook","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2025082700590595000_54.7.78.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.03.004"},{"key":"2025082700590595000_54.7.78.18","unstructured":"European Medicines Agency, 2014. Jardiance (Emapgliflozin) public assessment report [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002677\/WC500168594.pdf [Accessed 22 June 2016]."},{"key":"2025082700590595000_54.7.78.19","doi-asserted-by":"publisher","DOI":"10.1177\/0145721715607643"},{"key":"2025082700590595000_54.7.78.20","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70084-6"},{"key":"2025082700590595000_54.7.78.21","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2105"},{"key":"2025082700590595000_54.7.78.22","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2673"},{"key":"2025082700590595000_54.7.78.23","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12188"},{"key":"2025082700590595000_54.7.78.24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12503"},{"key":"2025082700590595000_54.7.78.25","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-3055"},{"key":"2025082700590595000_54.7.78.26","doi-asserted-by":"crossref","unstructured":"Ridderstraele M , et al . Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week, randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol\u00a0 2014;2:691\u2013700.","DOI":"10.1016\/S2213-8587(14)70120-2"},{"key":"2025082700590595000_54.7.78.27","doi-asserted-by":"crossref","unstructured":"Shyangdan D , et al . SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open\u00a0 2016; 6: e009417.","DOI":"10.1136\/bmjopen-2015-009417"},{"key":"2025082700590595000_54.7.78.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"2025082700590595000_54.7.78.29","doi-asserted-by":"crossref","unstructured":"Zinman B , et al . Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes \u2013 supplementary appendix . N Engl J Med 2015; DOI: 10.1056\/NEJMoa1504720.","DOI":"10.1056\/NEJMoa1504720"},{"key":"2025082700590595000_54.7.78.30","unstructured":"Food and Drug Administration, 2008. Guidance for industry diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [online]. Available: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm071627.pdf [Accessed 22 June 2016]."},{"key":"2025082700590595000_54.7.78.31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S2213-8587(16)00084-X","article-title":"SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?","volume":"4","author":"Wilding","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2025082700590595000_54.7.78.32","first-page":"1","article-title":"SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis","volume":"9","author":"Medicines and Healthcare products Regulatory Agency","year":"2016","journal-title":"Drug Safety Update"},{"key":"2025082700590595000_54.7.78.33","unstructured":"European Medicines Agency, 2016. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2016\/02\/WC500202388.pdf [Accessed 22 June 2016]."},{"key":"2025082700590595000_54.7.78.34","unstructured":"National Institute for Health and Care Excellence, 2015. Empagliflozin in combination therapy for treating type 2 diabetes (TA336) [online]. Available: https:\/\/www.nice.org.uk\/guidance\/ta336 [Accessed 22 June 2016]."},{"key":"2025082700590595000_54.7.78.35","unstructured":"National Institute for Health and Care Excellence, 2016. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390) [online]. Available: https:\/\/www.nice.org.uk\/guidance\/ta390 [Accessed 22 June 2016]."},{"key":"2025082700590595000_54.7.78.36","unstructured":"Scottish Medicines Consortium, 2014. Empagliflozin (Jarndice) [online]. Available: https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/993_14_empagliflozin_Jardiance [Accessed 22 June 2016]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2016.6.0411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:59:17Z","timestamp":1756281557000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2016.6.0411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7,14]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1136\/dtb.2016.6.0411"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2016.6.0411","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}